Lyell Immunopharma (LYEL) Other financing activities (2020 - 2026)
Lyell Immunopharma (LYEL) posted Other financing activities of $26000.0 for Q1 2026, down 85.64% sequentially from $181000.0 in Q4 2025.
Lyell Immunopharma (LYEL) Other financing activities (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Other financing activities for 7 years, with the latest figure at $26000.0 in Q1 2026.
- Quarterly Other financing activities changed N/A year-over-year to $26000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $391000.0 (down 65.85% YoY) and the FY2025 annual result came in at $365000.0, down 70.75% from the prior year.
- Other financing activities declined to $26000.0 in Q1 2026 per LYEL's latest filing, from $181000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $8.7 million in Q4 2022 and troughed at -$3.2 million in Q3 2022.
- A 5-year average of $823000.0 and a median of $182500.0 in 2025 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2022 and 2024: Other financing activities plunged 712.1% in 2022, then jumped 623.84% in 2024.
- Over 5 years, Other financing activities stood at $8.7 million in 2022, then plunged by 98.26% to $151000.0 in 2023, then surged by 623.84% to $1.1 million in 2024, then tumbled by 83.44% to $181000.0 in 2025, then plunged by 85.64% to $26000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $26000.0, $181000.0, and $184000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 496,000.00 |
| Jun 30, 2026 | 496,000.00 |
| Mar 31, 2026 | 26,000.00 |
| Mar 31, 2026 | 26,000.00 |
| Dec 31, 2025 | 181,000.00 |
| Dec 31, 2025 | 181,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Dec 31, 2024 | 1.09 Mn |
| Dec 31, 2024 | 1.09 Mn |
| Sep 30, 2024 | -655,000.00 |
| Sep 30, 2024 | -655,000.00 |
| Jun 30, 2024 | 707,000.00 |
| Jun 30, 2024 | 707,000.00 |
| Mar 31, 2024 | 103,000.00 |
| Mar 31, 2024 | 103,000.00 |
| Dec 31, 2023 | 151,000.00 |
| Dec 31, 2023 | 151,000.00 |
| Sep 30, 2023 | -1.01 Mn |
| Sep 30, 2023 | -1.01 Mn |